LXRX vs. VSTM, EBS, VNDA, XOMA, IRWD, CDXS, SGMO, ACHV, RGLS, and DOMH
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), and Dominari (DOMH). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals vs.
Verastem (NASDAQ:VSTM) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
Verastem has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Lexicon Pharmaceuticals' return on equity of -107.38% beat Verastem's return on equity.
Verastem received 133 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 65.32% of users gave Verastem an outperform vote while only 64.31% of users gave Lexicon Pharmaceuticals an outperform vote.
88.4% of Verastem shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 6.8% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Verastem has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Verastem presently has a consensus target price of $13.88, indicating a potential upside of 106.17%. Lexicon Pharmaceuticals has a consensus target price of $3.67, indicating a potential upside of 954.85%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Verastem.
Verastem has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Verastem is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Verastem had 22 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 26 mentions for Verastem and 4 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.57 beat Verastem's score of 0.28 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.
Summary
Verastem and Lexicon Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LXRX) was last updated on 3/28/2025 by MarketBeat.com Staff
